Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk

Jie Gao; Xinghan Liu; Linting Wei; Dan Niu; Jiali Wei; Li Wang; Heng Ge; Meng Wang; Qiaoling Yu; Tianbo Jin; Tian Tian; Zhijun Dai; Rongguo Fu

doi:10.18632/oncotarget.12847

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk

Jie Gao _, Xinghan Liu, Linting Wei, Dan Niu, Jiali Wei, Li Wang, Heng Ge, Meng Wang, Qiaoling Yu, Tianbo Jin, Tian Tian, Zhijun Dai and Rongguo Fu

PDF | HTML | How to cite

Oncotarget. 2016; 7:77950-77957. https://doi.org/10.18632/oncotarget.12847

Metrics: PDF 2051 views | HTML 2268 views | ?

Abstract

Jie Gao1,*, Xinghan Liu2,*, Linting Wei1,*, Dan Niu3, Jiali Wei4, Li Wang1, Heng Ge1, Meng Wang2, Qiaoling Yu5, Tianbo Jin6, Tian Tian2, Zhijun Dai2, Rongguo Fu1

1Department of Nephrology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

2Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

3Department of Nephrology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

4Department of Nephrology, Hainan general hospital, Haikou 570311, China

5Department of Pathology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

6National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an 710069, China

*These authors have contributed equally to this work

Correspondence to:

Jie Gao, email: [email protected]

Rongguo Fu, email: [email protected]

Keywords: monocyte chemoattractant protein-1, IgA nephropathy, polymorphism, risk, case-control study

Received: September 16, 2016 Accepted: October 12, 2016 Published: October 24, 2016

ABSTRACT

Monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 stimulate inflammation response by activating and recruiting monocytes/macrophages. MCP-1 and CCR2 polymorphisms were reported to be associated with various diseases. To explore the relationship between MCP-1 and CCR2 polymorphisms and IgA nephropathy (IgAN), we conducted this case-control study by enrolling 351 IgAN patients and 310 health controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate potential associations of MCP-1 and CCR2 polymorphisms with susceptibility and clinical parameters of IgAN. No statistical differences between IgAN group and the control group in the MCP-1 -2518 and CCR2 +190 genotypic groups were observed (P > 0.05). Individuals with MCP-1 -2518 GG genotypes had a higher blood pressure (GG vs. AA+AG: OR = 1.79, 95% CI = 1.07-2.99, P = 0.026) and Lee’s grade (GG vs. AA+AG: OR = 2.05, 95% CI = 1.19-3.54, P = 0.009; GG vs. AA: OR = 2.24, 95% CI = 1.19-4.20, P = 0.01), compared with patients with AA/AG genotypes. A significant association between CCR2 +190 polymorphism and Lee’s grades was observed (GA+AA vs. GG: OR = 2.66, 95% CI = 1.63-4.35, P < 0.001; GA vs. AA+GG: OR = 2.27, 95% CI = 1.39-3.70, P = 0.001). Our results indicated that MCP-1 and CCR2 polymorphisms may influence the progression of IgAN, but not increase/decrease its susceptibility.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12847

Publication Alerts

Research Papers:

Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk

Abstract